Illumina, Inc. $ILMN Stock: Lido Advisors LLC Boosts Holdings

Lido Advisors LLC increased its position in Illumina, Inc. (NASDAQ:ILMN) by 61.5% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,084 shares of the life sciences company’s stock after purchasing an additional 2,698 shares during the period. Lido Advisors LLC’s holdings in Illumina were worth $1,939,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Signature Equity Partners LLC lifted its stake in Illumina by 246.5% during the third quarter. Signature Equity Partners LLC now owns 149 shares of the life sciences company’s stock worth $41,000 after purchasing an additional 106 shares during the last quarter. Fiduciary Financial Advisors acquired a new position in Illumina in the second quarter worth $26,000. MCF Advisors LLC boosted its holdings in Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 100 shares during the period. Keating Financial Advisory Services Inc. bought a new stake in Illumina during the second quarter valued at $32,000. Finally, Rakuten Securities Inc. bought a new stake in Illumina during the second quarter valued at $33,000. 89.42% of the stock is currently owned by institutional investors.

Key Stories Impacting Illumina

Investors following ILMN have been watching these stories:

• Positive Sentiment: An updated valuation estimate raised Illumina’s fair value to $261.45 per share from $248.90, offering a potential upside reference. Illumina Stock Sees Modest Fair Value Lift
• Positive Sentiment: Illumina expanded its molecular residual disease research portfolio with a duplex-sequencing workflow and was selected to provide whole-genome sequencing for Singapore’s SG-INSIGHT study, supporting its clinical oncology and precision-medicine ambitions. Illumina Unveils Duplex Sequencing Workflow for MRD Research
• Negative Sentiment: Director Keith Meister sold 280,091 shares for approximately $61.1 million across November 9–11, cutting his direct stake substantially. The scale of the sales could concern investors, although he retained a sizable holding. SEC filing

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ILMN. Sanford C. Bernstein reissued a “market perform” rating and set a $215.00 target price on shares of Illumina in a report on Friday, July 31st. JPMorgan Chase & Co. decreased their price target on shares of Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a report on Friday, October 30th. Deutsche Bank lowered shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Evercore restated an “underperform” rating on shares of Illumina in a research note on Friday, October 30th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $244.24.

Illumina Stock Performance

Shares of NASDAQ ILMN traded down $2.54 during midday trading on Friday, hitting $207.01. 1,229,158 shares of the company’s stock were exchanged, compared to its average volume of 2,291,458. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05. The stock’s 50 day moving average price is $249.02 and its 200-day moving average price is $179.64. The firm has a market cap of $31.30 billion, a P/E ratio of 35.63, a PEG ratio of 2.84 and a beta of 1.46. Illumina, Inc. has a twelve month low of $112.65 and a twelve month high of $309.35.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same period last year, the firm earned $1.34 EPS. The firm’s revenue was up 4.2% compared to the same quarter last year. Equities research analysts anticipate that Illumina, Inc. will post 5.43 EPS for the current year.

Insider Activity

In other news, Director Keith Meister sold 299,336 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $217.96, for a total value of $65,243,274.56. Following the completion of the transaction, the director owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. This represents a 17.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold a total of 1,881,899 shares of company stock valued at $415,905,954 over the last ninety days. Corporate insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.